Loading...
Loading...
NRX Pharmaceuticals, Inc.
NRX Pharmaceuticals, Inc.. Spoken Alpha tracks NRXP's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks NRXP's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 8/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Spoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NRXP.
curl https://api.spokenalpha.com/v1/companies/NRXP| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.74 | $2.74 | +0.1% | +0.6% | +2.3% |
| Q4 FY2026 | $2.98 | $2.84 | +4.8% | +3.0% | +0.4% |
| Q3 FY2026 | $3.05 | $2.81 | +8.5% | -7.1% | -7.8% |
| Q2 FY2026 | $2.80 | $2.79 | +0.4% | +2.2% | +4.9% |
| Q1 FY2025 | $2.94 | $2.79 | +5.4% | +3.3% | +4.2% |
| Q4 FY2025 | $2.87 | $2.80 | +2.4% | -4.8% | -2.4% |
| Q3 FY2025 | $3.02 | $3.05 | -1.1% | -3.3% | -1.1% |
| Q2 FY2025 | $3.13 | $2.88 | +8.6% | +0.2% | -1.7% |
| Q1 FY2024 | $2.96 | $3.00 | -1.3% | -2.7% | -5.5% |
| Q4 FY2024 | $3.39 | $3.00 | +13.1% | -6.7% | -4.8% |
CEO since 2022 • 10/16 beats (63%) • guidance suspended Q3 FY2026